Catalog No.
YHJ46901
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Ile22-Val235
Predicted molecular weight
25.92 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q99795
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Cell surface A33 antigen, GPA33, Glycoprotein A33
Prognostic Significance and Immune Environment Analysis Using PANoptosis Molecular Clustering in Gastric Cancer., PMID:40317125
Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma., PMID:39949781
GPA33 expression in colorectal cancer can be induced by WNT inhibition and targeted by cellular therapy., PMID:39472498
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten., PMID:39168519
Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function., PMID:38891073
Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation., PMID:38604503
Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment., PMID:37509078
Diagnostic gastrointestinal markers in primary lung cancer and pulmonary metastases., PMID:37349623
Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer., PMID:35409691
Single-Cell Transcriptomics Reveals Discrete Steps in Regulatory T Cell Development in the Human Thymus., PMID:34937744
Clinical and diagnostic potential of regulatory T cell markers: From bench to bedside., PMID:34922022
An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma., PMID:34183802
GPA33 is expressed on multiple human blood cell types and distinguishes CD4+ central memory T cells with and without effector function., PMID:33728639
Intestinal phenotype is maintained by Atoh1 in the cancer region of intraductal papillary mucinous neoplasm., PMID:33275808
Selective Photokilling of Colorectal Tumors by Near-Infrared Photoimmunotherapy with a GPA33-Targeted Single-Chain Antibody Variable Fragment Conjugate., PMID:32396000
GPA33: A Marker to Identify Stable Human Regulatory T Cells., PMID:32366581
A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis., PMID:32215766
A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis., PMID:31928310
An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy., PMID:31891487
Dual Radionuclide Theranostic Pretargeting., PMID:31483993
Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy., PMID:30912951
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma., PMID:30429889
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers., PMID:30082472
A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer., PMID:29935333
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer., PMID:29866746
Transcriptomic Analysis of CD4+ T Cells Reveals Novel Immune Signatures of Latent Tuberculosis., PMID:29602771
Identification and Functional Analysis of Gene Regulatory Sequences Interacting with Colorectal Tumor Suppressors., PMID:29589301
Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer., PMID:28705917
A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma., PMID:28226180
Heterogeneous expression of A33 in colorectal cancer: possible explanation for A33 antibody treatment failure., PMID:27272411
Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment., PMID:26692229
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates., PMID:26596724
A hypermorphic epithelial β-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations., PMID:26398937
Intestinal-specific activatable Myb initiates colon tumorigenesis in mice., PMID:26300002
CF750-A33scFv-Fc-Based Optical Imaging of Subcutaneous and Orthotopic Xenografts of GPA33-Positive Colorectal Cancer in Mice., PMID:26090413
Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease., PMID:26035389
Preparation of an engineered safer immunotoxin against colon carcinoma based on the ribotoxin hirsutellin A., PMID:25752204
Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas., PMID:25712076
Identification of male-specific amh duplication, sexually differentially expressed genes and microRNAs at early embryonic development of Nile tilapia (Oreochromis niloticus)., PMID:25199625
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer., PMID:24691674
68Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers., PMID:24589653
Colon tumour secretopeptidome: insights into endogenous proteolytic cleavage events in the colon tumour microenvironment., PMID:23684732
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer., PMID:23294608
Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids., PMID:23230278
Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules., PMID:22872125
Production and characterization of scFvA33T1, an immunoRNase targeting colon cancer cells., PMID:22748038
Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin., PMID:22718791
Increased interaction between vaccinia virus proteins A33 and B5 is detrimental to infectious extracellular enveloped virion production., PMID:22623782
The A33-dependent incorporation of B5 into extracellular enveloped vaccinia virions is mediated through an interaction between their lumenal domains., PMID:22623777
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET., PMID:22068895
For research use only. Not for human or drug use.
